Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Intidhar Labidi

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid TumorsHiba Mechahougui, Léna Royston, Catia Vieira Gomes, et al.
Gynecologic Oncology|December 18, 2013
Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasmsKevin M Elias, S Intidhar Labidi-Galy, Allison F Vitonis, et al.
Swiss Medical Weekly|April 3, 2023
Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort studyNoémie Lang, Aurélie Ayme, Chang Ming, et al.
Familial Cancer|April 29, 2023
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literatureKetty Hu-Heimgartner, Noémie Lang, Aurélie Ayme, et al.
Breast Cancer Research and Treatment|January 13, 2019
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsAlex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, et al.
Scientific Reports|November 3, 2020
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Gynecologic Oncology|November 23, 2019
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysisCécile Le Page, Kurosh Rahimi, Manuel Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian CancerS Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
Gynecologic Oncology|October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancersS Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2026
Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid TumorsHiba Mechahougui, Léna Royston, Catia Vieira Gomes, et al.
Gynecologic Oncology|December 18, 2013
Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasmsKevin M Elias, S Intidhar Labidi-Galy, Allison F Vitonis, et al.
Swiss Medical Weekly|April 3, 2023
Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort studyNoémie Lang, Aurélie Ayme, Chang Ming, et al.
Familial Cancer|April 29, 2023
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literatureKetty Hu-Heimgartner, Noémie Lang, Aurélie Ayme, et al.
Breast Cancer Research and Treatment|January 13, 2019
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patientsAlex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, et al.
Scientific Reports|November 3, 2020
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Scientific Reports|April 29, 2020
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypesSolene De Talhouet, Julien Peron, Aurelie Vuilleumier, et al.
Gynecologic Oncology|November 23, 2019
Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysisCécile Le Page, Kurosh Rahimi, Manuel Rodrigues, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Location of Mutation in <i>BRCA2</i> Gene and Survival in Patients with Ovarian CancerS Intidhar Labidi-Galy, Timothée Olivier, Manuel Rodrigues, et al.
Gynecologic Oncology|October 13, 2019
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancersS Intidhar Labidi-Galy, Thibault de La Motte Rouge, Olfa Derbel, et al.
Pageof 3